CClinicalTrials.gg
Enrolling by invitationNCT06785246GrasshopperUpdated Jan 21, 2025

Grasshopper: a Novel Clinical Dashboard for Radiologists

An interventional study of Grasshopper dashboard in Chest Infection and Pulmonary Edema - Acute, sponsored by Kaiser Permanente. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-01-21.

Sponsored by Kaiser Permanente · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 1 year after the study started (first participant enrolled Jan 2024, registered Jan 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
100,000
Allocation
Not applicable
Sex
All
01

Study summary

Does a radiology clinical dashboard increase radiologist use of specific reporting language for chest X-rays (CXRs) and thereby decrease rates of unnecessary Emergency Department (ED) prescriptions and follow-up imaging?

Read the detailed description

Chest X-rays (CXR) are the most common radiologic exam, comprising nearly one third of total KPNC imaging volume. Despite high CXR utilization, diagnostic yield is frequently low, partly due to the paucity of clinical information provided to radiologists at the time of CXR interpretation, resulting in frequent nonspecific CXR assessments which include terms like "opacities" instead of diagnostic terms such as "pulmonary edema" or "pneumonia". This may contribute to over-treatment and unnecessary follow-up CT imaging. This study proposes the production deployment, active promotion, and evaluation of an innovative clinical dashboard called Grasshopper for radiologists to provide pertinent clinical information at the time of CXR interpretation. The dashboard leverages the electronic medical record to programmatically retrieve, and display select clinical notes, patient lab values, and vital signs. The Grasshopper study aims to prospectively evaluate the impact of Grasshopper on CXR report specificity in ED settings across 15 KPNC service areas, and on downstream care process measures such as prescription and imaging utilization.

02

Conditions studied

  • Chest Infection
  • Pulmonary Edema - Acute

Browse trials for

Keywords

  • AI
  • Emergency Department
  • Radiology
  • Imaging
03

In context

Pulmonary Edema

138 studies on the registry are indexed under Pulmonary Edema; 24 are open to participants now.

This study's planned enrollment of 100,000 is above the median of 68 across 72 interventional studies indexed under Pulmonary Edema.

Browse Pulmonary Edema studies →

Lead sponsor

Kaiser Permanente is the lead sponsor of 385 studies on the registry; 41 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Kaiser Permanente Northern California CXR is ordered during emergency room visit or inpatient hospitalization

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100,000 participants (estimated)

Study arms

  • Experimental
    Grasshopper CXR Dashboard

    Grasshopper CXR Dashboard

    Other: Grasshopper dashboard

Interventions

  • OtherGrasshopper dashboard

    Computer dashboard application for radiologists that displays relevant clinical information directly from the medical record

06

What researchers measure

Primary outcomes

  1. Number of Diagnostic CXR Reports

    Number of CXR reports that employ diagnostic terms in the report impression (e.g. "negative", "pneumonia", "pulmonary edema"), compared with baseline standard of care report impressions.

    Time frame: Through study completion, an average of 18 months.

Secondary outcomes

  1. Number of Prescriptions after Stat CXR

    Number of antibiotic and diuretic prescriptions the patient receives after having undergone a stat CXR, compared with baseline standard of care.

    Time frame: Through study completion, at an average of 18 months.

  2. Number of CT Imaging exams after Stat CXR

    Number of follow-up CT imaging exams that a patient receives after having undergone a stat CXR, compared with baseline standard of care.

    Time frame: Through study completion, at an average of 18 months.

07

Study locations

1 site
  • Kaiser Permanente Northern California Division of Research
    Pleasanton, California 94566, United States
08

References and documents

Individual participant data

Plan to share: Undecided — Pending further organizational guidance

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06785246
Lead sponsor
Kaiser Permanente
Responsible party
Jason D. Balkman (Principal Investigator, Kaiser Permanente) — Principal investigator
First posted
Jan 21, 2025
Start date
Jan 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jan 21, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion